HDAC6 and tauopathy: Here, we report that the novel HDAC6 inhibitor T-518 harboring oxadiazole instead of hydroxamate as the ZBG acts as a potent, selective, orally bioavailable, and brain-penetrant HDAC6 inhibitor, and that T-518 has therapeutic effects in a mouse model of tauopathy.